https://doi.org/10.1186/s13601-019-0296-1

Caillaud et al. Clin Transl Allergy

Open Access

Short-acting β2-agonists (SABA) bronchodilator sales and outdoor mould in central France

D. M. Caillaud^{1*}, S. Martin², C. Ségala², N. Dupuy³, M. Thibaudon³ and D. Muti¹

(2019) 9:56

Background: Temporal ecological studies have shown that outdoor moulds are associated with severe asthma exacerbations, as emergency department visits or hospitalisations. The aim of this was to assess the associations between daily sales of short-acting β 2-agonists (SABA), a specific and frequent treatment for control of mild asthma exacerbations in children and young adults, and outdoor mould concentrations in the central France area over a 5 year period.

Methods: The relationship between daily changes in mould (25 species) concentrations and daily SABA sales within a population of patients aged 6 to 39 years in a middle-size town of central France (approximately 127,000) was obtained from social security database and analysed with generalized additive models, taking into account confound-ing factors (air pollution, weather conditions, pollen counts and trend).

Results: Daily SABA sales (mean, SD) rose from 17.3 (9.7) in 2010 to 22.7 (12) in 2015. The relative risk (RR [95% CI]) of SABA sales associated with an interquartile increase in mould concentration was significant in the whole population for *Alternaria* 1.06 [1.002–1.12]. When the influence of age and sex was accounted for, the relationship was significant only in 6–12 years old males for *Alternaria* 1.21 [1.04–1.41] and *Aspergillus–Penicillium* 1.08 [1.04–1.12].

Conclusions: Daily SABA sales are positively associated with *Alternaria* spores in the general population of children and young adults. The association between daily SABA sales and temporal changes to *Alternaria* and *Aspergillus–Peni-cillium* in male children indicate that outdoor moulds contribute to asthma morbidity.

Keywords: Alternaria, Aspergillus-Penicillium, Asthma, Mould, Outdoor, Spores, Pharmacoepidemiology

Introduction

Asthma exacerbations, as shown by emergency department visits or hospitalizations, are associated with outdoor moulds, but it is difficult to identify which mould taxa are responsible for these severe and infrequent events. In contrast, short-acting β 2-agonists agonists (SABA) are widely used by patients experiencing mild asthma exacerbations, which translates into increased sales. SABA sales have been successfully used to illustrate the relationship between asthma and outdoor air pollution [1]. This study will therefore test, over a 5 year period, the relationship between exposure to individual

63003 Clermont-Ferrand, France

Full list of author information is available at the end of the article



outdoor mould taxa in the general population of central France, differentiated by age and gender, with SABA sales.

Methods

Records of all SABA treatments prescribed for people living in the demographically stable Clermont-Ferrand area (approximately 285,000 inhabitants) were provided for the study period (2010–2012; 2014–2015) from the public health insurance database, which covers 80% of the French urban population. Owing to missing data due to technical reasons, 2013 was omitted. The health outcome was defined as the number of "cases" per day, whereby a case is defined as the reimbursement of a SABA treatment. SABA sales were excluded for children <6 years because of the uncertainty of asthma diagnosis [2] and for adults > 39 years, because they are also used for acute

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*}Correspondence: dcaillaud@chu-clermontferrand.fr

¹ Service de Pneumologie-Allergologie, Hôpital Gabriel

Montpied, Clermont Auvergne University, Montalembert Street,

exacerbations of COPD. This study was entirely anonymous and so approval from the French Ethics Committee was not required. Mould samples were collected daily from mid-February to early October, as described previously [3]. Molds and pollens were sampled on the rooftop of a building of the University Hospital, with no nearby buildings obstructing air circulation. Samples for microscopic analysis were collected with a coat paper using a 7 days recording volumetric trap of the Hirst design, at a suction rate of 10 L/min. The tape representing 1 week of sampling was cut into 7 fragments, each representing 1 day, and transferred to a glass slide. After application of a reactive colouring solution, the mean spore concentration, expressed as total number of spores per cubic meter of air (spores/m³), was determined using 400× optical microscopy along 1 longitudinal sweep per slide. Spores were identified at the genus level only, since in most cases it was not possible to identify spore species. *Cladosporium* and *Alternaria* taxa collected for 5 years, other mould taxa for 3 years. Data on influenza epidemics was obtained from the national network for transmissible disease surveillance. Air pollution (PM_{10} , O^3 , NO_2), meteorological data, age and sex were available from the database.

Data were analyzed by overdispersed Poisson regression with generalized additive models (GAMs). Using non-parametric smoothing functions, GAMs allow flexible control of the effect of trend and seasonal components and of confounding factors whose relationship with asthma is not linear. The construction of the model began with the introduction of the long-term trend and seasonal variations, using a cubic smoothing spline of the day of the study. Holidays, days of the week and influenza occurrence were then introduced as dummy variables. Quantitative meteorological, pollution and pollen variables were introduced as penalized cubic splines, with different lags tested. Finally, mould counts were introduced in the form of penalized cubic splines, with lags of up to 7 days. The effect of mould on asthma in the short term is expressed as a relative risk (RR and 95% CI) for an increase of the interquartile range of grains (statistical program: SM).

Results

Table 1 shows the 10 moulds present in outdoor air for more than 90 days (among 25 individual taxa identified) and the trends in the daily concentrations of Alternaria and Aspergillus–Penicillium are represented in Fig. 1. The daily SABA sales (mean, SD) for 6 to 39 year old subjects rose significantly from 17.3 (9.7) in 2010 to 22.7 (12.3) in 2015. Across the entire population, the RR [95% CI] of SABA medication sales associated with an interguartile increase in spore concentration was significant for Alternaria 1.06 [1.002–1.12]. When the influence of age and sex was considered (Table 2), the relationship was significant only in male children aged 6-12 years for Alternaria and Aspergillus-Penicillium. The shapes (with 95% CI) of the mould-SABA sale relationship in male children aged 6-12 for Aspergillus-Penicillium (Fig. 2a) and Alternaria (Fig. 2b) suggest that the effect of Aspergillus-Penicillium on SABA sales is linear whereas the effect of Alternaria spores is approximately linear up to a saturation point of approximately 400 spores/m³."

Discussion

Our study, using SABA sales as a very specific marker for asthma attacks within the 6 to 39 year-old population (mean of 20 SABA sales per day across several years), reveals an association between *Alternaria* spore concentration and daily SABA sales across the general

Table 1 Outdoor mould taxa in Clermont-Ferrand, 2010–2012 and 2014–2015

Fungal spore taxa	Number of days ^a	Number of spores/m ³						
		Mean (SD)	Min	Q1	Median	Q3	Max	
Alternaria	507	108 (139)	20	26	60	124	1240	
Aspergillus–Penicillium	171	183 (320)	26	51	103	206	3503	
Cladosporium	854	3397 (4417)	20	771	2048	4000	36,263	
Epicoccum	248	69 (61)	25	26	51	77	437	
Erysiphe	195	54 (45)	25	26	31	75	283	
Ganoderma	265	109 (75)	26	51	103	154	488	
Helicomyces	91	68 (108)	25	26	31	62	675	
Myxomycetes	176	108 (173)	26	26	51	103	1388	
Torula	164	46 (31)	25	26	26	51	231	
Ustilago	189	170 (252)	26	31	77	186	1645	

^a Number of days with detectable levels of each mold across all monitored days





Table 2 Outdoor moulds and SABA sales by age and gender, 2010–2012, 2014–2015

Mould	Lag (days)	IQR	Sex	Age (years)			
				6–12		13–39	
				RR	CI 95%	RR	CI 95%
Alternaria	0–2	66	М	1.21	[1.04–1.41]	1.001	[0.993-1.008]
			F	1.04	[0.99–1.1]	1.05	[0.97-1.13]
Aspergillus–Penicillium	1	154	М	1.08	[1.04-1.12]	1	[0.999–1.00]
			F	1	[0.999–1.001]	0.98	[0.93–1.03]

Significant results (p < 0.05) are in italic characters. Lag: associations were estimated for optimal lag defined according to the associations reported for individual lags. For example: *Alternaria* Lag 0–2 corresponds to the mean *Alternaria* concentration for D0, D1 and D2

population. Epidemiological studies examining the relationship between outdoor *Alternaria* and asthma in people not known to be sensitized to *Alternaria*, are scarce. A Californian study [4] demonstrated an association between asthma symptom scores and *Alternaria* levels, while an Australian study found *Alternaria* exposure to be significantly associated with asthma hospitalization [5]. In Saint-John, Canada (asthma ED visits of 3.5 per day), the concentration of *Alternaria* spores was associated with a 4.5% increase in ED visits [6]. Our study, by showing that outdoor *Alternaria* moulds are associated with a 6% increase in SABA sales, confirms the latter result on a larger sample of the general population.

Page 4 of 5



In addition to *Alternaria*, the association between outdoor individual spores and SABA sales was significant for *Aspergillus–Penicillium* spores in children. Only 1 Canadian study has reported the effects of outdoor *Aspergillus–Penicillium* spores on asthma. In Ontario, an adjusted 2.34% significant increase in child ED visits was observed with an increase in *Aspergillus–Penicillium* spore concentration [7].

increase on the x-axis

Among children, the relationship between SABA sales and mould concentrations was observed only in boys. Only 1 study reported a significant increase in daily hospitalizations in boys in association with two outdoor fungal taxa, deuteromycetes (which include *Alternaria* and *Aspergillus–Penicillium*) and basidiomycetes [8].

The main strength of the present study lies in the extremely large regionally representative dataset comprising subjects between 6 and 39 years of age, and living within 15 km of the spore trap. The concentrations of outdoor spores, with Cladosporium predominating, are in line with other studies performed in European temperate climates. We used appropriate statistical tools to reveal the shape of the curve for every mould spore studied, while adjusting for potentially confounding factors (such as air pollution, meteorology and pollens). The lack of knowledge about mould sensitization in our general urban population is a potential limitation. As the genera Aspergillus and Penicillium are morphologically indistinguishable, laboratories list them together as Aspergillus-Penicillium type. Outdoor mould effect will vary by climatic region [9]. Data on rhinovirus and respiratory syncitial virus, which are known, confounders of asthma exacerbations were unfortunately not available in France during the study period.

In conclusion, this study, performed in central France over a 5-year period, showed that daily changes of *Alternaria* outdoor spores were associated with increased SABA sales in the general population of children and adults up to the age of 40. Outdoor *Aspergillus–Penicillium*, and *Alternaria* mould spore concentrations were associated with increased SABA sales in boys aged 6 to 12 years. These results suggest that moulds contribute to mild asthma exacerbations in the general population. Further studies in other geographical areas with different climatic conditions are needed to complement these results.

Acknowledgements

P Vidal for providing insurance daily purchases of anti-allergic treatment sales and to S Pellier for providing air pollution data.

Authors' contributions

DC, MT, ND, DM and ND provided mould data and contributed to the design, data analyses, and drafted the manuscript. SM and CS contributed to the design, statistical script, and data analysis. ND provided mould data. All authors participated in revision of the study manuscript and approval of the final version. All authors had full access to all the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. DC is the guarantor of the paper, taking responsibility for the integrity of the work as a whole, from inception to published article. All authors read and approved the final manuscript.

Funding

Acknowledgement of partial funding by Astra-Zeneca, Boehringer Ingelheim, ALK-Abello. The researchers are totally independent of the funder.

Availability of data and materials

Contact C Segala for an anonymized database of this study.

Ethics approval and consent to participate

This study was entirely anonymous, so approval from the French Ethics Committee was not required. Professor Caillaud, as a state employee of the university, was authorized to have access to the general database of the French public health insurance system.

Competing interests

DC has received research grant support and/or speaker/consulting fees from ALK-Abello, Astra-Zeneca, Boehringer-Ingelheim, Chiesi, Novartis and GSK. DM has received speaker/consulting fees from Astra-Zeneca, Boehringer-Ingelheim, Chiesi, Mylan and Roche. CS, SM, ND and MT have no interest to declare.

Author details

 ¹ Service de Pneumologie-Allergologie, Hôpital Gabriel Montpied, Clermont Auvergne University, Montalembert Street, 63003 Clermont-Ferrand, France.
² SEPIA-Santé, 56150 Baud, France.
³ Réseau National de Surveillance Aérobiologique, 69690 Brussieu, France.

Received: 6 August 2019 Accepted: 17 October 2019 Published online: 25 October 2019

References

- 1. Menichini F, Mudu P. Drug consumption and air pollution: an overview. Pharmacoepidemiol Drug Saf. 2010;19:1300–15.
- GINA. Global Initiative for Asthma. Global strategy for asthma management and prevention. http://www.ginasthma.org. 2018.
- Caillaud D, Cheriaux M, Martin S, Segala C, Dupuy N, Evrard B, et al. Short-term effect of outdoor mould spore exposure on prescribed allergy medication sales in Central France. Clin Exp Allergy. 2018;48(7):837–45.

- Delfino RJ, Zeiger RS, Seltzer JM, Street DH, Matteucci RM, Anderson PR, et al. The effect of outdoor fungal spore concentrations on daily asthma severity. Environ Health Perspect. 1997;105:622–35.
- Tham R, Vicendese D, Dharmage SC, Hyndman RJ, Newbigin E, Lewis E, et al. Associations between outdoor fungal spores and childhood and adolescent asthma hospitalizations. J Allergy Clin Immunol. 2017;139(1140–1147):e1144.
- Stieb DM, Beveridge RC, Brook JR, Smith-Doiron M, Burnett RT, Dales RE, et al. Air pollution, aeroallergens and cardiorespiratory emergency department visits in Saint John, Canada. J Expo Anal Environ Epidemiol. 2000;10:461–77.
- Dales RE, Cakmak S, Burnett RT, Judek S, Coates F, Brook JR. Influence of ambient fungal spores on emergency visits for asthma to a regional children's hospital. Am J Respir Crit Care Med. 2000;162:2087–90.
- Cakmak S, Dales RE, Judek S, Coates F. Does socio-demographic status influence the effect of pollens and molds on hospitalization for asthma? Results from a time-series study in 10 Canadian cities. Ann Epidemiol. 2005;15:214–8.
- Tham R, Dharmage SC, Taylor PE, Katelaris CH, Vicendese D, Abramson MJ, et al. Outdoor fungi and child asthma health service attendances. Pediatr Allergy Immunol. 2014;25:439–49.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

